| P2093 | author name string | Igor P Pogribny | |
| P2860 | cites work | Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients | Q86120631 |
| | Drug-induced acute liver failure | Q86481862 |
| | Dysregulated miR1254 and miR579 for cardiotoxicity in patients treated with bevacizumab in colorectal cancer | Q87269128 |
| | Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large AtheroGene study | Q87782489 |
| | AACR Cancer Progress Report 2016 | Q88472766 |
| | Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia | Q24539231 |
| | MicroRNAs: target recognition and regulatory functions | Q24609584 |
| | Circulating microRNAs as stable blood-based markers for cancer detection | Q24652098 |
| | Circulating microRNAs, potential biomarkers for drug-induced liver injury | Q24656209 |
| | Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review | Q26746063 |
| | Clinical significance of microRNAs in chronic and acute human leukemia | Q26749533 |
| | Serum microRNA-21 as a diagnostic marker for lung carcinoma: a systematic review and meta-analysis | Q27023210 |
| | Mammalian microRNAs predominantly act to decrease target mRNA levels | Q27860535 |
| | The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 | Q27860849 |
| | MicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena? | Q28076541 |
| | Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases | Q28131780 |
| | Market withdrawal of new molecular entities approved in the United States from 1980 to 2009 | Q28237701 |
| | Nonalcoholic fatty liver disease: a systematic review | Q28263139 |
| | Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma | Q29614238 |
| | Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: a meta-analysis. | Q31161472 |
| | Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer | Q33654179 |
| | Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma | Q33736118 |
| | Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study | Q33793516 |
| | Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine | Q34033136 |
| | Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis | Q34082773 |
| | Identification of a metastasis-specific MicroRNA signature in human colorectal cancer | Q34461847 |
| | Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis | Q34778143 |
| | A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction | Q34962538 |
| | Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma | Q35246395 |
| | Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis | Q35526554 |
| | Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease | Q35584190 |
| | Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. | Q35840874 |
| | Circulating microRNAs and Outcome in Patients with Acute Heart Failure | Q35845355 |
| | Absolute quantification of cell-free microRNAs in cancer patients | Q35987412 |
| | Diagnostic value of circulating miR-21: An update meta-analysis in various cancers and validation in endometrial cancer | Q36140281 |
| | Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. | Q36187981 |
| | A Five-miRNA Panel Identified From a Multicentric Case-control Study Serves as a Novel Diagnostic Tool for Ethnically Diverse Non-small-cell Lung Cancer Patients | Q36251395 |
| | The increasing toll of adolescent cancer incidence in the US. | Q36290042 |
| | Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human. | Q36381558 |
| | Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. | Q36942423 |
| | Diagnostic Value of Cell-free Circulating MicroRNAs for Obesity and Type 2 Diabetes: A Meta-analysis. | Q36998610 |
| | Circulating microRNAs predict biochemical recurrence in prostate cancer patients | Q37081843 |
| | Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital | Q37346819 |
| | Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population | Q37444289 |
| | Heart Disease and Cancer Deaths - Trends and Projections in the United States, 1969-2020. | Q37450583 |
| | Circulating microRNAs as Potential Biomarkers of Infectious Disease | Q37643903 |
| | A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer | Q37744279 |
| | Serum microRNAs as powerful cancer biomarkers | Q37773488 |
| | Development of blood biomarkers for drug-induced liver injury: an evaluation of their potential for risk assessment and diagnostics | Q38122649 |
| | Circulating microRNAs as novel biomarkers for the early diagnosis of acute coronary syndrome. | Q38125100 |
| | The validity of circulating microRNAs in oncology: five years of challenges and contradictions. | Q38198366 |
| | Circulating miRNAs as biomarkers for neurodegenerative disorders. | Q38214427 |
| | The emerging role of circulating microRNAs as biomarkers in autoimmune diseases | Q38222306 |
| | Circulating microRNA biomarker studies: pitfalls and potential solutions | Q38267750 |
| | The role for microRNAs in drug toxicity and in safety assessment | Q38367620 |
| | Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. | Q38680300 |
| | Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. | Q38771051 |
| | Are circulating microRNAs peripheral biomarkers for Alzheimer's disease? | Q38855547 |
| | Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging? | Q39141563 |
| | Variability in, variability out: best practice recommendations to standardize pre-analytical variables in the detection of circulating and tissue microRNAs | Q39183943 |
| | Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma | Q39229733 |
| | Prospective study on circulating MicroRNAs and risk of myocardial infarction | Q39583273 |
| | Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer | Q40579865 |
| | Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis | Q40965602 |
| | Challenges in using circulating miRNAs as cancer biomarkers | Q41072824 |
| | A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. | Q41152266 |
| | Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States | Q41626076 |
| | Systematic literature review and clinical validation of circulating microRNAs as diagnostic biomarkers for colorectal cancer | Q42157952 |
| | Diagnostic value of miR-30d-5p and miR-125b-5p in acute myocardial infarction | Q42555901 |
| | The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. | Q43137450 |
| | Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction | Q50105196 |
| | A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson's disease. | Q51620455 |
| | MicroRNAs in Cardiovascular Disease. | Q53641839 |
| | Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study. | Q53789480 |
| | Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. | Q54356342 |
| | Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. | Q54363176 |
| | Circulating microRNAs as potential markers of human drug-induced liver injury | Q60609564 |
| | Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain | Q62128946 |
| | Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy | Q85032624 |
| | MicroRNAs in cancer | Q86065522 |
| P921 | main subject | microRNA | Q310899 |
| | biomarker | Q864574 |
| P304 | page(s) | 1535370217731291 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Experimental Biology and Medicine | Q15716535 |
| P1476 | title | MicroRNAs as biomarkers for clinical studies | |